bluebird bio, Inc. (LON:0HOH)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 36.39M |
| Revenue (ttm) | 80.45M |
| Net Income (ttm) | -154.78M |
| Shares Out | n/a |
| EPS (ttm) | -15.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,257 |
| Average Volume | 2,235 |
| Open | 3.900 |
| Previous Close | 3.900 |
| Day's Range | 3.900 - 3.900 |
| 52-Week Range | 3.900 - 33.200 |
| Beta | n/a |
| RSI | 25.86 |
| Earnings Date | May 15, 2025 |
About bluebird bio
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development... [Read more]
Financial Performance
In 2024, bluebird bio's revenue was $83.81 million, an increase of 184.12% compared to the previous year's $29.50 million. Losses were -$240.72 million, 13.6% more than in 2023.
Financial numbers in USD Financial StatementsNews
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”)...
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity
Bluebird Bio revised its agreement with Carlyle ... Full story available on Benzinga.com
Bluebird bio soars on amended deal with Carlyle, SK Capital
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their ...
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender of...
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings...
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9%
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“...
BlueBird Shares Are Up Today: What's Going On?
Bluebird Bio Inc. (NASDAQ: BLUE) shares are ... Full story available on Benzinga.com
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio, Inc. (NASDAQ: BLUE) received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday. Ayrmid has proposed to acquire Bluebird for an upfront cash payment of $4.50 per sh...
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Key M&A Developments: NVDA, BLUE, and DLTR Lead Market News
Key M&A Developments: NVDA, BLUE, and DLTR Lead Market News
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more
Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid
Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premium Offer
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premium Offer
bluebird bio sees higher offer for company from Ayrmid Pharma
Bluebird bio receives non-binding bid for up to $110.5 million
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (...
The Citi US Economic Surprise Index is climbing back into positive territory
The Citi US Economic Surprise Index is a widely followed indicator that measures how recent economic data compares to consensus expectations. How It Works The index rises when economic data releases (...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUE
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of blueb...